The Experts below are selected from a list of 10920 Experts worldwide ranked by ideXlab platform
Takaaki Konuma - One of the best experts on this subject based on the ideXlab platform.
-
effect of abo blood group incompatibility on the outcome of single unit cord blood transplantation after Myeloablative Conditioning
Biology of Blood and Marrow Transplantation, 2014Co-Authors: Takaaki Konuma, Seiko Kato, Nobuhiro Ohno, Maki Oiwamonna, Yasuhiro Ebihara, Shinji Mochizuki, Koichiro Yuji, Toyotaka Kawamata, Norihide Jo, Kazuaki YokoyamaAbstract:Abstract ABO blood group incompatibility between donor and recipient has been associated with poor transplant outcomes in allogeneic hematopoietic stem cell transplantation. However, its effect on the outcome of cord blood transplantation (CBT) has yet to be clarified. We retrospectively analyzed 191 adult patients who received single-unit CBT after Myeloablative Conditioning for malignant disease in our institute. Major mismatch showed a significantly lower incidence of platelet engraftment compared with ABO match as a reference (hazard ratio, .57; P = .01). Nevertheless, there was no increase in graft-versus-host disease, transplant-related mortality, and overall mortality after ABO-incompatible CBT. These data suggested that donor–recipient ABO incompatibility does not have a significant impact on outcome after Myeloablative CBT for hematological malignancies.
-
unrelated cord blood transplantation after Myeloablative Conditioning in adults with acute myelogenous leukemia
Biology of Blood and Marrow Transplantation, 2008Co-Authors: Satoshi Takahashi, Akira Tomonari, Nobuhiro Tsukada, Takaaki Konuma, Seiko Kato, Senji Kasahara, Aki Sato, Fumihiko Monma, Fumitaka Nagamura, Tohru IsekiAbstract:Abstract We analyzed the disease-specific outcomes of adult acute myelogenous leukemia (AML) patients treated with unrelated cord blood transplantation (CBT) after Myeloablative Conditioning. Between August 1998 and February 2008, 77 adult patients with AML were treated with unrelated CBT. All patients received 4 fractionated 12 Gy total body irradiation (TBI) and chemotherapy as Myeloablative Conditioning. The median age was 45 years, the median weight was 55 kg, the median number of nucleated cells was 2.44 × 10 7 /kg, and the median number of CD34-positive cells was 1.00 × 10 5 /kg. All patients received a single and HLA mismatched cord blood unit. The cumulative incidence of neutrophil recovery at day 50 and platelet recovery at day 200 was 94.8% and 91.7%, respectively. A higher CD34-positive cell dose was associated with faster hematopoietic recovery. The cumulative incidence of grade III to IV acute graft-versus-host disease (aGVHD) and extensive-type chronic GVHD (cGVHD) was 25.1% and 28.6%, respectively. With a median follow-up of 78 months, the probability of event-free survival (EFS) at 5 years was 62.8%. The 5-year cumulative incidence of treatment related-mortality (TRM) and relapse was 9.7%, 25.8%, respectively. In multivariate analyses, the risk factor identified for event free survival (EFS) was disease status and cytogenetics. These results suggest that unrelated CBT after Myeloablative Conditioning could be safely and effectively used for adult patients with AML.
-
Unrelated cord blood transplantation after Myeloablative Conditioning in adults with ALL.
Bone Marrow Transplantation, 2008Co-Authors: Satoshi Takahashi, Akira Tomonari, Nobuhiro Tsukada, Takaaki Konuma, Seiko Kato, Senji Kasahara, Aki Sato, Fumihiko Monma, Fumitaka NagamuraAbstract:We analyzed the disease-specific outcomes of adult ALL treated with cord blood transplantation (CBT) after Myeloablative Conditioning. Between October 2000 and November 2007, 27 adult patients with ALL were treated with unrelated CBT. All patients received four fractionated 12 Gy TBI and chemotherapy as Myeloablative Conditioning. The median age was 36 years, the median weight was 57 kg and the median number of nucleated cells was 2.47 × 107/kg. All patients received a single and HLA-mismatched cord blood unit. The cumulative incidence of neutrophil recovery at day 30 and platelet recovery at day 200 was 92.6 and 92.3%, respectively. With a median follow-up of 47 months, the probability of EFS at 5 years was 57.2%. The 5-year cumulative incidence of TRM and relapse was 3.7 and 27.4%, respectively. These results suggest that unrelated CBT after Myeloablative Conditioning could be safely and effectively used for adult patients with ALL.
-
Unrelated cord blood transplantation after Myeloablative Conditioning in patients with acute leukemia aged between 50 and 55 years.
Bone Marrow Transplantation, 2006Co-Authors: Takaaki Konuma, Satoshi Takahashi, Akira Tomonari, Nobuhiro Tsukada, Tohru Iseki, Arinobu Tojo, Michihiro Uchiyama, Kenji Fukuno, Shigetaka AsanoAbstract:Unrelated cord blood transplantation after Myeloablative Conditioning in patients with acute leukemia aged between 50 and 55 years
-
Unrelated cord blood transplantation after Myeloablative Conditioning for adult patients with refractory anemia.
International Journal of Hematology, 2005Co-Authors: Tohru Iseki, Satoshi Takahashi, Akira Tomonari, Takaaki Konuma, Michihiro Uchiyama, Kenji Fukuno, Kashiya Takasugi, Yasushi Soda, Nobuhiro OhnoAbstract:We report the results of unrelated cord blood transplantation (CBT) after Myeloablative Conditioning in 3 patients with myelodysplastic syndrome-refractory anemia (MDS-RA). All patients were treated with total body irradiation, cytosine arabinoside (Ara-C), and cyclophosphamide, followed by unrelated HLA-mismatched CBT. Granulocyte colony-stimulating factor was infused continuously, starting 12 hours before Ara-C therapy and continuing until the end of Ara-C therapy. All patients received standard cyclosporine and methotrexate therapy as graft-versus-host disease prophylaxis. All patients had myeloid reconstitution, and the times to reach an absolute neutrophil count >0.5 × 109/L were 23, 20, and 26 days. All patients showed full donor chimerism at the time of the first bone marrow examination (on day +42, +43, and +62) after CBT. All patients are alive and free of disease at between 17 and 39 months after CBT. These results suggest that adult MDS-RA patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT.
Carlos Solano - One of the best experts on this subject based on the ideXlab platform.
-
single unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan thiotepa fludarabine and atg as Myeloablative Conditioning regimen
Bone Marrow Transplantation, 2012Co-Authors: Jaime Sanz, Juan Carlos Hernandez Boluda, Carmen Martin, M Gonzalez, Christelle Ferra, D P Serrano, C D De Heredia, Cristina Barrenetxea, A M Martinez, Carlos SolanoAbstract:Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as Myeloablative Conditioning regimen
Anna Ghiso - One of the best experts on this subject based on the ideXlab platform.
-
unmanipulated haploidentical bone marrow transplantation and post transplant cyclophosphamide for hematologic malignanices following a Myeloablative Conditioning an update
Bone Marrow Transplantation, 2015Co-Authors: Andrea Bacigalupo, Alida Dominietto, Anna Ghiso, C Di Grazia, T Lamparelli, F Gualandi, S Bregante, M T Van Lint, Simona Geroldi, Silvia LuchettiAbstract:Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a Myeloablative Conditioning: an update
-
unmanipulated haploidentical bmt following non Myeloablative Conditioning and post transplantation cy for advanced hodgkin s lymphoma
Bone Marrow Transplantation, 2014Co-Authors: A M Raiola, Alida Dominietto, Riccardo Varaldo, Anna Ghiso, Federica Galaverna, S Bramanti, Elisabetta Todisco, Barbara Sarina, Laura Giordano, Adalberto IbaticiAbstract:Unmanipulated haploidentical BMT following non-Myeloablative Conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma
-
Unmanipulated haploidentical BMT following non-Myeloablative Conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma
Bone Marrow Transplantation, 2013Co-Authors: A M Raiola, Alida Dominietto, Riccardo Varaldo, Anna Ghiso, Federica Galaverna, S Bramanti, Elisabetta Todisco, Barbara Sarina, Laura Giordano, Adalberto IbaticiAbstract:Unmanipulated haploidentical BMT following non-Myeloablative Conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma
-
Unmanipulated Haploidentical Bone Marrow Transplantation and Post-Transplant Cyclophosphamide for Hematologic Malignanices Following A Myeloablative Conditioning.
Blood, 2012Co-Authors: Andrea Bacigalupo, Alida Dominietto, Anna Ghiso, C Di Grazia, T Lamparelli, F Gualandi, S Bregante, M T Van Lint, Anna Maria Raiola, Riccardo VaraldoAbstract:Abstract 3034 Despite a large number of unrelated donors (UD), not more than 30% of patients who have activated a donor search, undergo an allogeneic UD stem cell transplant. HLA haploidentical family members are being increasingly considered as an alternative donors, both using T cell depleted or T cell replete grafts. Post-transplant high dose cyclophosphamide (PT-CY), introduced by the Baltimore group, has shown very promising results following non Myeloablative Conditioning regimens. We are now reporting 50 patients with high risk hematologic malignancies, who received a Myeloablative regimen, followed by unmanipulated haploidentical bone marrow transplant (hBMT) and PT-CY. The Myeloablative Conditioning consisted of thiotepa (10 mg/kg), busulfan (9,6 mg/m2), fludarabine (150 mg/m2)(n=35), or total body irradiation (9,9–12 Gy), fludarabine (120 mg/m2) (n=15). The median age was 42 years (18–66); 23 patients were in remission and 27 had active disease; 10 patients were receiving a second allograft. Graft versus host disease (GvHD) prophylaxis consisted in PT-CY on day+3 and +5, cyclosporine (from day 0), and mycophenolate (from day +1). The median nucleated cell dose was 3.6 ×108/kg (range: 1,4 – 7,7). The median time to neutrophil counts of >0.5×109/L was 18 days (range, 13–30 days) and to platelet counts of >20×109/L 23 days (range, 14 – 58 days), respectively. There was no correlation between infused number of nucleated cells and days of neutrophil engraftment. The cumulative incidence of engraftment was 90%for neutrophils and 86% for platelets. Three patients died before engraftment, and 2 patients had autologous recovery: 45 patients (90%) had full donor chimerism on day +30. The cumulative incidence of grade II-III acute GvHD was 12%, and of moderate chronic GvHD 10%. With a median follow up for surviving patients of 333 days (149–623), the cumulative incidence of transplant related mortality is 18%, and the rate of relapse 26%. The actuarial 22 months disease free survival is 68% for patients in remission and 37% for patients with active disease (p In conclusion, a Myeloablative Conditioning regimen followed by h-BMT with PT-CY, results in a low risk of acute and chronic GvHD and encouraging rates of transplant related mortality and disease free survival. Disclosures: No relevant conflicts of interest to declare.
Alida Dominietto - One of the best experts on this subject based on the ideXlab platform.
-
unmanipulated haploidentical bone marrow transplantation and post transplant cyclophosphamide for hematologic malignanices following a Myeloablative Conditioning an update
Bone Marrow Transplantation, 2015Co-Authors: Andrea Bacigalupo, Alida Dominietto, Anna Ghiso, C Di Grazia, T Lamparelli, F Gualandi, S Bregante, M T Van Lint, Simona Geroldi, Silvia LuchettiAbstract:Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a Myeloablative Conditioning: an update
-
unmanipulated haploidentical bmt following non Myeloablative Conditioning and post transplantation cy for advanced hodgkin s lymphoma
Bone Marrow Transplantation, 2014Co-Authors: A M Raiola, Alida Dominietto, Riccardo Varaldo, Anna Ghiso, Federica Galaverna, S Bramanti, Elisabetta Todisco, Barbara Sarina, Laura Giordano, Adalberto IbaticiAbstract:Unmanipulated haploidentical BMT following non-Myeloablative Conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma
-
Unmanipulated haploidentical BMT following non-Myeloablative Conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma
Bone Marrow Transplantation, 2013Co-Authors: A M Raiola, Alida Dominietto, Riccardo Varaldo, Anna Ghiso, Federica Galaverna, S Bramanti, Elisabetta Todisco, Barbara Sarina, Laura Giordano, Adalberto IbaticiAbstract:Unmanipulated haploidentical BMT following non-Myeloablative Conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma
-
Unmanipulated Haploidentical Bone Marrow Transplantation and Post-Transplant Cyclophosphamide for Hematologic Malignanices Following A Myeloablative Conditioning.
Blood, 2012Co-Authors: Andrea Bacigalupo, Alida Dominietto, Anna Ghiso, C Di Grazia, T Lamparelli, F Gualandi, S Bregante, M T Van Lint, Anna Maria Raiola, Riccardo VaraldoAbstract:Abstract 3034 Despite a large number of unrelated donors (UD), not more than 30% of patients who have activated a donor search, undergo an allogeneic UD stem cell transplant. HLA haploidentical family members are being increasingly considered as an alternative donors, both using T cell depleted or T cell replete grafts. Post-transplant high dose cyclophosphamide (PT-CY), introduced by the Baltimore group, has shown very promising results following non Myeloablative Conditioning regimens. We are now reporting 50 patients with high risk hematologic malignancies, who received a Myeloablative regimen, followed by unmanipulated haploidentical bone marrow transplant (hBMT) and PT-CY. The Myeloablative Conditioning consisted of thiotepa (10 mg/kg), busulfan (9,6 mg/m2), fludarabine (150 mg/m2)(n=35), or total body irradiation (9,9–12 Gy), fludarabine (120 mg/m2) (n=15). The median age was 42 years (18–66); 23 patients were in remission and 27 had active disease; 10 patients were receiving a second allograft. Graft versus host disease (GvHD) prophylaxis consisted in PT-CY on day+3 and +5, cyclosporine (from day 0), and mycophenolate (from day +1). The median nucleated cell dose was 3.6 ×108/kg (range: 1,4 – 7,7). The median time to neutrophil counts of >0.5×109/L was 18 days (range, 13–30 days) and to platelet counts of >20×109/L 23 days (range, 14 – 58 days), respectively. There was no correlation between infused number of nucleated cells and days of neutrophil engraftment. The cumulative incidence of engraftment was 90%for neutrophils and 86% for platelets. Three patients died before engraftment, and 2 patients had autologous recovery: 45 patients (90%) had full donor chimerism on day +30. The cumulative incidence of grade II-III acute GvHD was 12%, and of moderate chronic GvHD 10%. With a median follow up for surviving patients of 333 days (149–623), the cumulative incidence of transplant related mortality is 18%, and the rate of relapse 26%. The actuarial 22 months disease free survival is 68% for patients in remission and 37% for patients with active disease (p In conclusion, a Myeloablative Conditioning regimen followed by h-BMT with PT-CY, results in a low risk of acute and chronic GvHD and encouraging rates of transplant related mortality and disease free survival. Disclosures: No relevant conflicts of interest to declare.
Tohru Iseki - One of the best experts on this subject based on the ideXlab platform.
-
Unrelated cord blood transplantation after Myeloablative Conditioning in adults with advanced myelodysplastic syndromes
Bone Marrow Transplantation, 2010Co-Authors: Aki Sato, Satoshi Takahashi, Nobuhiro Tsukada, Seiko Kato, Fumitaka Nagamura, Tohru Iseki, Toshiro Kawakita, T Yagyu, Arinobu TojoAbstract:We analyzed the disease-specific outcomes of adult patients with advanced myelodysplastic syndrome (MDS) treated with cord blood transplantation (CBT) after Myeloablative Conditioning. Between August 1998 and June 2009, 33 adult patients with advanced MDS were treated with unrelated CBT. The diagnoses at transplantation included refractory anemia with excess blasts (n=7) and MDS-related secondary AML (sAML) (n=26). All patients received four fractionated 12 Gy TBI and chemotherapy as Myeloablative Conditioning. The median age was 42 years, the median weight was 55 kg and the median number of cryopreserved nucleated cells was 2.51 × 107 cells per kg. The cumulative incidence of neutrophil recovery at day 50 was 91%. Neutrophil recovery was significantly faster in sAML patients (P=0.04). The cumulative incidence of plt recovery at day 200 was 88%. Plt recovery was significantly faster in CMV seronegative patients (P
-
unrelated cord blood transplantation after Myeloablative Conditioning in adults with acute myelogenous leukemia
Biology of Blood and Marrow Transplantation, 2008Co-Authors: Satoshi Takahashi, Akira Tomonari, Nobuhiro Tsukada, Takaaki Konuma, Seiko Kato, Senji Kasahara, Aki Sato, Fumihiko Monma, Fumitaka Nagamura, Tohru IsekiAbstract:Abstract We analyzed the disease-specific outcomes of adult acute myelogenous leukemia (AML) patients treated with unrelated cord blood transplantation (CBT) after Myeloablative Conditioning. Between August 1998 and February 2008, 77 adult patients with AML were treated with unrelated CBT. All patients received 4 fractionated 12 Gy total body irradiation (TBI) and chemotherapy as Myeloablative Conditioning. The median age was 45 years, the median weight was 55 kg, the median number of nucleated cells was 2.44 × 10 7 /kg, and the median number of CD34-positive cells was 1.00 × 10 5 /kg. All patients received a single and HLA mismatched cord blood unit. The cumulative incidence of neutrophil recovery at day 50 and platelet recovery at day 200 was 94.8% and 91.7%, respectively. A higher CD34-positive cell dose was associated with faster hematopoietic recovery. The cumulative incidence of grade III to IV acute graft-versus-host disease (aGVHD) and extensive-type chronic GVHD (cGVHD) was 25.1% and 28.6%, respectively. With a median follow-up of 78 months, the probability of event-free survival (EFS) at 5 years was 62.8%. The 5-year cumulative incidence of treatment related-mortality (TRM) and relapse was 9.7%, 25.8%, respectively. In multivariate analyses, the risk factor identified for event free survival (EFS) was disease status and cytogenetics. These results suggest that unrelated CBT after Myeloablative Conditioning could be safely and effectively used for adult patients with AML.
-
Unrelated cord blood transplantation after Myeloablative Conditioning in patients with acute leukemia aged between 50 and 55 years.
Bone Marrow Transplantation, 2006Co-Authors: Takaaki Konuma, Satoshi Takahashi, Akira Tomonari, Nobuhiro Tsukada, Tohru Iseki, Arinobu Tojo, Michihiro Uchiyama, Kenji Fukuno, Shigetaka AsanoAbstract:Unrelated cord blood transplantation after Myeloablative Conditioning in patients with acute leukemia aged between 50 and 55 years
-
Unrelated cord blood transplantation after Myeloablative Conditioning for adult patients with refractory anemia.
International Journal of Hematology, 2005Co-Authors: Tohru Iseki, Satoshi Takahashi, Akira Tomonari, Takaaki Konuma, Michihiro Uchiyama, Kenji Fukuno, Kashiya Takasugi, Yasushi Soda, Nobuhiro OhnoAbstract:We report the results of unrelated cord blood transplantation (CBT) after Myeloablative Conditioning in 3 patients with myelodysplastic syndrome-refractory anemia (MDS-RA). All patients were treated with total body irradiation, cytosine arabinoside (Ara-C), and cyclophosphamide, followed by unrelated HLA-mismatched CBT. Granulocyte colony-stimulating factor was infused continuously, starting 12 hours before Ara-C therapy and continuing until the end of Ara-C therapy. All patients received standard cyclosporine and methotrexate therapy as graft-versus-host disease prophylaxis. All patients had myeloid reconstitution, and the times to reach an absolute neutrophil count >0.5 × 109/L were 23, 20, and 26 days. All patients showed full donor chimerism at the time of the first bone marrow examination (on day +42, +43, and +62) after CBT. All patients are alive and free of disease at between 17 and 39 months after CBT. These results suggest that adult MDS-RA patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT.
